person · Reporting owner

Brady Todd C

Disclosed activity across 5 companies

Tapewire entity: 40835
SEC CIK: 0001579179

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aldeyra Therapeutics, Inc.ALDX · Entity 6839	Director · President and CEO	June 03, 2026	June 05, 2026
Avidity Biosciences, Inc.RNA · Entity 11854	Director	June 11, 2020	June 12, 2020
Outlook Therapeutics, Inc.ONS · Entity 608	Director	October 26, 2017	October 30, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aldeyra Therapeutics, Inc.

Report date June 03, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,721,298	Reported balance After 2026-06-03 transaction · row 1 1 source row Row 1 · 2026-06-03 · Purchase · Acquired 250,000 · Balance 1,721,298 F1: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

Avidity Biosciences, Inc.

Report date June 11, 2020 · Filed June 12, 2020

This filing explicitly reported no securities owned.

Outlook Therapeutics, Inc.

Report date October 26, 2017 · Filed October 30, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-10-26	Direct	15,000	Reported balance After 2017-10-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-10-26 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Evoke Pharma Inc

Report date December 16, 2025 · Filed December 17, 2025

Section 16 reporting ended · disclosed 2025-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-12-16 transaction · row 1 1 source row Row 1 · 2025-12-16 · Other · Disposed 27 · Balance 0 F1: On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the "Offer Price").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.41	Direct	Reported balance After 2025-12-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-12-17 · Disposition to issuer · Disposed 1,218 · Balance 0 F2: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.45	Direct	Reported balance After 2025-12-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-17 · Disposition to issuer · Disposed 5,833 · Balance 0 F2: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45	Direct	Reported balance After 2025-12-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-12-17 · Disposition to issuer · Disposed 1,187 · Balance 0 F2: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the "Offer Price").

F2: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.

F-star Therapeutics, Inc.

Report date November 20, 2020 · Filed March 09, 2023

Section 16 reporting ended · disclosed 2023-03-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-03-08 transaction · row 1 1 source row Row 1 · 2023-03-08 · Other · Disposed 15,004 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023. F2: (Continued from footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2031-06-04	Direct	Reported balance After 2023-03-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.41 · Expires 2032-06-17	Direct	Reported balance After 2023-03-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 · Expires 2026-07-27	Direct	Reported balance After 2020-11-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-20 · Other · Disposed 11,000 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.27 · Expires 2027-06-14	Direct	Reported balance After 2020-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-20 · Other · Disposed 5,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.99 · Expires 2028-06-17	Direct	Reported balance After 2020-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-20 · Other · Disposed 5,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2029-07-09	Direct	Reported balance After 2020-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-11-20 · Other · Disposed 7,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2030-06-23	Direct	Reported balance After 2020-11-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-11-20 · Other · Disposed 7,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.79 · Expires 2021-11-23	Direct	Reported balance After 2020-11-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-20 · Other · Disposed 10,964 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023.

F2: (Continued from footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020.

F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)).

F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option.

F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option.

F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 02, 2020 Filed Mar 5, 2020 00:44 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantBonus Units · Derivative	450,865	$0.00 Strike: $3.78	$0.00	Disclosure SEC source: 0000899243-20-007060 · doc4.xml · derivative · entry 3 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,865 Underlying: Common Stock · 450,865 shares Expires not disclosed F3 · derivative.exercise_price: The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $3.78. F3 · derivative.exercise_date: The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $3.78. F3 · derivative.expiration_date: The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $3.78. Read SEC document
March 02, 2020 Filed Mar 5, 2020 00:44 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantEmployee Stock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $3.78	$0.00	Disclosure SEC source: 0000899243-20-007060 · doc4.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-03-01 F2 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020. Read SEC document
March 02, 2020 Filed Mar 5, 2020 00:44 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantCommon Stock	250,000	$0.00	$0.00	Disclosure SEC source: 0000899243-20-007060 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902,216 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document
December 31, 2019 Filed Jan 2, 2020 17:09 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantCommon Stock	7,832	$0.00	$0.00	Disclosure SEC source: 0001209191-20-000382 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,057 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document
December 16, 2019 Filed Dec 18, 2019 12:35 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	20,000	$5.10	$101,908.00	Disclosure SEC source: 0000899243-19-029509 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,216 Read SEC document
September 30, 2019 Filed Oct 1, 2019 16:47 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantCommon Stock	3,597	$0.00	$0.00	Disclosure SEC source: 0001209191-19-051314 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,225 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document
September 30, 2019 Filed Oct 2, 2019 11:36 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	8,710	$5.68	$49,483.25	Disclosure SEC source: 0000899243-19-024582 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,216 F1 · kind: The purchase of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.41 to $5.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document
September 23, 2019 Filed Sep 25, 2019 11:40 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	8,680	$5.81	$50,432.54	Disclosure SEC source: 0000899243-19-024225 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,506 F1 · kind: The purchase of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document
September 18, 2019 Filed Sep 20, 2019 11:37 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	14,288	$5.91	$84,464.94	Disclosure SEC source: 0000899243-19-023982 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614,826 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.80 to $5.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document
September 16, 2019 Filed Sep 17, 2019 20:21 UTC Amendment	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	3,000	$6.03	$18,090.00	Disclosure SEC source: 0000899243-19-023735 · doc4a.xml · nonDerivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,538 Read SEC document
September 16, 2019 Filed Sep 17, 2019 11:35 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	3,000	$6.03	$18,090.00	Disclosure SEC source: 0000899243-19-023718 · doc4.xml · nonDerivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,991 Read SEC document
September 13, 2019 Filed Sep 17, 2019 20:21 UTC Amendment	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	18,547	$5.90	$109,358.68	Disclosure SEC source: 0000899243-19-023735 · doc4a.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,538 F1 · shares: Includes 8,547 shares that were inadvertently omitted from the original Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.79 to $6.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document
September 13, 2019 Filed Sep 17, 2019 11:35 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	10,000	$5.79	$57,900.00	Disclosure SEC source: 0000899243-19-023718 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,991 Read SEC document
September 10, 2019 Filed Sep 11, 2019 20:05 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	10,000	$5.39	$53,937.00	Disclosure SEC source: 0000899243-19-023317 · doc4.xml · nonDerivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,991 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.375 to $5.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document
September 09, 2019 Filed Sep 11, 2019 20:05 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	10,000	$4.89	$48,887.00	Disclosure SEC source: 0000899243-19-023317 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,991 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.88 to $4.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 2,937 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2019. Read SEC document
July 10, 2019 Filed Jul 11, 2019 08:55 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $4.62	$0.00	Disclosure SEC source: 0001209191-19-041764 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-07-09 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on July 10, 2019, the date of the Issuer's 2019 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document
June 28, 2019 Filed Jul 1, 2019 09:00 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantCommon Stock	3,354	$0.00	$0.00	Disclosure SEC source: 0001209191-19-039565 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,628 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to receive shares in lieu of cash compensation for services as a director and committee member. Read SEC document
May 02, 2019 Filed May 3, 2019 17:44 UTC	Evoke Pharma Inc EVOK · Entity 71094	GrantStock Option (Right to Buy) · Derivative	34,000	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001209191-19-027498 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2029-05-01 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (5/2/2020), subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document
March 29, 2019 Filed Apr 2, 2019 16:03 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantCommon Stock	1,180	$0.00	$0.00	Disclosure SEC source: 0001209191-19-022335 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,274 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document
March 05, 2019 Filed Mar 7, 2019 22:20 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantBonus Units · Derivative	45,329	$0.00 Strike: $8.05	$0.00	Disclosure SEC source: 0000899243-19-006729 · doc4.xml · derivative · entry 3 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,329 Underlying: Common Stock · 45,329 shares Expires not disclosed F4 · derivative.exercise_price: The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $8.05. F4 · derivative.exercise_date: The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $8.05. F4 · derivative.expiration_date: The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $8.05. Read SEC document
March 05, 2019 Filed Mar 7, 2019 22:20 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantEmployee Stock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $8.05	$0.00	Disclosure SEC source: 0000899243-19-006729 · doc4.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-03-04 F3 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2019. Read SEC document
March 05, 2019 Filed Mar 7, 2019 22:20 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantCommon Stock	250,000	$0.00	$0.00	Disclosure SEC source: 0000899243-19-006729 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,054 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · balance_after: Includes 3,571 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2018. Read SEC document
June 18, 2018 Filed Jun 19, 2018 16:28 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantStock Option (right to buy) · Derivative	5,500	$0.00 Strike: $13.99	$0.00	Disclosure SEC source: 0001209191-18-038560 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2028-06-17 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2018, the date of the Issuer's 2018 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document
April 26, 2018 Filed Apr 27, 2018 16:22 UTC	Evoke Pharma Inc EVOK · Entity 71094	GrantStock Option (Right to Buy) · Derivative	34,000	$0.00 Strike: $2.36	$0.00	Disclosure SEC source: 0001209191-18-026570 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2028-04-25 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (4/26/2019), subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document
March 06, 2018 Filed Mar 8, 2018 21:40 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantEmployee Stock Option (Right to Buy) · Derivative	217,293	$0.00 Strike: $8.60	$0.00	Disclosure SEC source: 0000899243-18-006819 · doc4.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,293 Underlying: Common Stock · 217,293 shares Expires 2028-03-05 F3 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2018. Read SEC document
March 06, 2018 Filed Mar 8, 2018 21:40 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantCommon Stock	101,269	$0.00	$0.00	Disclosure SEC source: 0000899243-18-006819 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,483 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · shares: Includes 4,550 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in June 2017 and 575 shares of common stock acquired under the Issuer's ESPP in December 2017. Read SEC document
January 02, 2018 Filed Jan 3, 2018 16:12 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantCommon Stock	852	$0.00	$0.00	Disclosure SEC source: 0001209191-18-000811 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,094 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document
October 26, 2017 Filed Oct 30, 2017 22:03 UTC	Outlook Therapeutics, Inc. ONS · Entity 608	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $1.32	$0.00	Disclosure SEC source: 0001209191-17-058363 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-10-26 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document
October 02, 2017 Filed Oct 3, 2017 16:04 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantCommon Stock	633	$0.00	$0.00	Disclosure SEC source: 0001209191-17-054996 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,242 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document
July 03, 2017 Filed Jul 5, 2017 16:08 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantCommon Stock	645	$0.00	$0.00	Disclosure SEC source: 0001209191-17-043254 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,609 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document
June 15, 2017 Filed Jun 16, 2017 16:49 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantStock Option (right to buy) · Derivative	5,500	$0.00 Strike: $14.27	$0.00	Disclosure SEC source: 0001209191-17-040567 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2027-06-14 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 15, 2017, the date of the Issuer's 2017 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document
May 03, 2017 Filed May 5, 2017 17:58 UTC	Evoke Pharma Inc EVOK · Entity 71094	GrantStock Option (Right to Buy) · Derivative	34,000	$0.00 Strike: $2.72	$0.00	Disclosure SEC source: 0001209191-17-030425 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2027-05-02 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (5/3/2018), subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document
March 03, 2017 Filed Mar 7, 2017 22:45 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantEmployee Stock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $5.10	$0.00	Disclosure SEC source: 0000899243-17-006712 · doc4.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-03-02 F2 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2017. Read SEC document
March 03, 2017 Filed Mar 7, 2017 22:45 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantCommon Stock	136,806	$0.00	$0.00	Disclosure SEC source: 0000899243-17-006712 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,214 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on March 3, 2017, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document
February 17, 2017 Filed Feb 21, 2017 21:32 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	PurchaseCommon Stock	22,223	$4.50	$100,003.50	Disclosure SEC source: 0000899243-17-004754 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,408 F1 · price: Represents shares of common stock purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 17, 2017. Read SEC document
November 23, 2016 Filed Nov 23, 2016 16:00 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantWarrant (right to buy) · Derivative	10,964	$0.00 Strike: $10.79	$0.00	Disclosure SEC source: 0000899243-16-034292 · doc4.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,964 Underlying: Common Stock · 10,964 shares Expires 2021-11-23 Read SEC document
November 23, 2016 Filed Nov 23, 2016 16:00 UTC	F-star Therapeutics, Inc. SBPH · Entity 115726	GrantCommon Stock	10,964	$9.12	$99,991.68	Disclosure SEC source: 0000899243-16-034292 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,964 Read SEC document
November 09, 2016 Filed Nov 14, 2016 23:15 UTC	Outlook Therapeutics, Inc. ONS · Entity 608	Exercise / conversionCommon Stock	28,985	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-16-014637 · marketforms-36766.xml · nonDerivative · entry 2 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of the Issuer's common stock. Read SEC document
November 09, 2016 Filed Nov 14, 2016 23:15 UTC	Outlook Therapeutics, Inc. ONS · Entity 608	ConversionRestricted Stock Units	28,985	$0.00	$0.00	Disclosure SEC source: 0001214659-16-014637 · marketforms-36766.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Granted pursuant to the Issuer's 2015 Equity Incentive Plan. F2 · shares: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of the Issuer's common stock. F3 · shares: The RSUs are subject to, and to vest must satisfy, both (a) performance-based vesting restrictions (the RSUs will satisfy the performance-based vesting restrictions upon the first to occur of (x) a change of control as defined in the award agreement and (y) the expiration of the 6 month lock-up period following the Issuer's initial public offering ("IPO"), subject to continued service through such event) and (b) time-based vesting restrictions (50% of the RSUs will satisfy the time-based vesting restrictions on each of the third and fourth anniversaries of July 11, 2013, subject to continued service through such dates). In addition, 100% of the RSUs will satisfy the time-based vesting restrictions upon the occurrence of a change of control, subject to continued service through such event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.